Physician profile
Soyoung Sung
NPI 1194786731
$4,685.10
in general payments reported to CMS, 2019-2025
15 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2021: $535 · 2022: $574 · 2023: $748 · 2024: $1,111 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,176.55 | 2019-2024 | Vabysmo, Lucentis |
| Mallinckrodt Hospital Products INC. | $656.32 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $500.70 | 2021-2024 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $344.57 | 2023-2025 | Eylea Hd, Eylea |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $312.88 | 2019 | |
| Astellas Pharma US INC | $303.73 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $243.64 | 2023-2025 | Syfovre |
| Allergan, INC. | $241.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $202.18 | 2019-2021 | |
| Genentech, INC. | $191.87 | 2025 | Susvimo |
| Bausch & Lomb Americas INC. | $147.80 | 2022-2024 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $137.25 | 2024 | Xdemvy |
| Abbvie INC. | $125.00 | 2025 | |
| Notal Vision, INC. | $80.89 | 2022 | |
| Alcon Vision LLC | $20.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soyoung Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.